De novo urothelial carcinoma in kidney transplant recipients: a single-center retrospective cohort study
Post-transplant UC in KTRs is associated with a more than twofold increased incidence compared with the general population and a disproportionate burden of upper tract and graft-involving tumors. Management must carefully balance oncologic control against preservation of transplant function in a setting where standard intra-vesical and systemic therapies are constrained by immunosuppression. These findings support risk-adapted lifelong urologic surveillance and highlight the need for dedicated treatment strategies tailored to immunosuppressed patients.
Authors
- Irena Goranova
- Sarah Weinberger (ORCID: https://orcid.org/0000-0002-4259-8990)
- Lukas Kurz (ORCID: https://orcid.org/0000-0001-6145-2877)
- Isabel Lichy (ORCID: https://orcid.org/0000-0002-1680-3604)
- Frank Friedersdorff (ORCID: https://orcid.org/0000-0002-3104-911X)
- Henning Plage (ORCID: https://orcid.org/0000-0002-7680-1870)
- Nadine Biernath
- Jonathan Jeutner (ORCID: https://orcid.org/0009-0009-7035-9127)
- Robert L. Peters
- Thorsten Schlomm
- Malte Lehnert
- Jacob Schmidt
- Bernhard Ralla
Institutions
- Humboldt-Universität zu Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Evangelisches Krankenhaus Königin Elisabeth Herzberge (DE)
Publication Details
- Journal
- International Urology and Nephrology
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1007/s11255-026-05026-2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00